Cellosign Overview
Cellosign has developed an application that enables efficient business processing between customer service representatives and customers. The application enables representatives to share documents interactively through real-time, bi-directional viewing and annotation of data, including eSignatures. By eliminating the barriers to digital mobile signatures, Cellosign enables call centers to increase transaction close rates while significantly reducing complexity.
Latest News
growth-positive
CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform
CellOrigin Biotech has announced a new round of investment by Kunlun Capital for the development of its iPSC-derived innate immune cells. The company has also received investment from Shulan Health and Nest. Bio Ventures. CellOrigin Biotech focuses on iPSC-derived innate immune cells and their applications in cancer immunotherapies. They hold patents for iPSC-derived CAR-Macrophage and are collaborating with research groups worldwide. The company aims to bring more effective, universal, and safe immune cell products to cancer patients. They have initiated investigator-initiated trials at the First Hospital of Zhejiang University and have recently launched a GMP facility in Hangzhou, China. Kunlun Capital is a long-term value investor that has invested in various companies, including CellOrigin Biotech.
Investment
| Sector | Business Software |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 0 |
| Investors | 0 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | cellosign.com |
Locations
Abba Eban Boulevard 16, Herzliyya, Israel
Photos & Videos
1 item(s)
